Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Eric So
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 50
- Beta
- 0.79
- Country
- CA
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 4.54
Financials
Revenue
$0.00-100.0%Net Income
$-33.72MEBITDA
$-28.86MFree Cash Flow
$-34.92MEPS (diluted)
$-1.39Shares Outstanding (diluted)
24.21M+6614.0%Operating Expenses
$28.89MCash & Debt
$83.75MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-113.14M | $-0.61 |
| 2024 | $0.00 | $-78.08M | $-3.91 |
| 2023 | $0.00 | $-40.04M | $-0.22 |
| 2022 | $0.00 | $-71.42M | $-0.43 |
| 2021 | $864.0K | $-32.22M | $-3221645.62 |
| 2020 | $0.00 | $-1.94M | $-0.05 |
| 2019 | $0.00 | $-101.0K | $-0.01 |
| 2018 | $0.00 | $-220.8K | $-0.69 |
| 2017 | $0.00 | $-127.0K | $-0.01 |
Valuation
CYBNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (2)
- Newsmarketbeat.com·1d ago·Negative
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright's 28th Annual Global Investment Conference.
View source ↗ - Newsmarketbeat.com·1d ago·Neutral
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company's mental health treatment pipeline.
View source ↗
Earnings
Typical surprise -93.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 13$-1.39 vs $-0.74miss
- Thu, Aug 14$-1.10 vs $-0.51miss
- Mon, Jun 30$-1.02 vs $-0.51miss
- Mon, Feb 10$-0.38 vs $-0.51beat
- Wed, Nov 13$-2.10 vs $-0.38miss
- Thu, Aug 8$-0.38 vs $-0.01miss
Estimates and results for CYBN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CYBN officers and directors.
- Bought
- $8.4m
- Sold
- —
7 trades
0 trades
- Halstead Michaelbought
- Glavine Paulbought
- So Eric H. L.bought
- So Eric H. L.bought
- Glavine Paulbought
- So Eric H. L.bought
- Glavine Paulbought
9 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CYBN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.